Biopharmaceutical company CStone Pharmaceuticals (HKEX:2616) on Friday announced European Commission approval of sugemalimab (Cejemly) in combination with platinum-based chemotherapy for first-line treatment of non-small cell lung cancer (NSCLC).
The drug becomes the first Chinese-developed anti-PD-L1 monoclonal antibody approved in Europe.
This approval was based on the GEMSTONE-302 Phase 3 trial, which demonstrated improved survival rates.
CStone has partnered with Swiss pharmaceutical company Ewopharma for commercialisation in Central and Eastern Europe and in Switzerland. The company is seeking further partnerships for Western Europe and other regions.
CStone plans to submit additional applications to the European Medicines Agency for indications in other cancer types.
Merck discontinues Phase 3 trials KEYNOTE-867 and KEYNOTE-630
Oncosure introduces Rapid Cancer Screening Test
Bayer and NextRNA collaborate on LncRNA-targeting therapeutics
GSK welcomes Delaware Supreme Court review of Zantac litigation
Fusion Antibodies expands collaboration with US National Cancer Institute
Telix Pharmaceuticals submits TLX101-CDx NDA to US FDA
Astellas initiates Phase 3 study for fezolinetant in breast cancer patients
Cantargia updates clinical trial timelines for nadunolimab
RedHill Biopharma's Opaganib receives US FDA orphan-drug designation